Litigation Details for AbbVie Inc. v. Hetero USA Inc. (D. Del. 2014)

« Back to Dashboard

AbbVie Inc. v. Hetero USA Inc. (D. Del. 2014)

Docket		Date Filed	2014-04-24
Court	District Court, D. Delaware	Date Terminated	2014-11-18
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,399,015; 8,470,347
Attorneys	Magdalena Spencer
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for AbbVie Inc. v. Hetero USA Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-24				External link to document

AbbVie Inc. v. Hetero USA Inc., 1:14-cv-00543: Litigation Summary and Patent Analysis

Last updated: August 25, 2026

AbbVie Inc. v. Hetero USA Inc., No. 1:14-cv-00543, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Hetero’s abbreviated new drug application for a generic version of AndroGel 1.62% testosterone gel. AbbVie asserted patents covering testosterone-gel formulations and their use in treating male hypogonadism. The case ended without a reported merits decision, and the public docket reflects resolution by agreement and dismissal rather than a trial judgment.

What drug and ANDA were at issue in AbbVie v. Hetero?

The dispute involved AndroGel 1.62%, a prescription testosterone product marketed by AbbVie and its predecessor commercial entities.

Item	Information
Brand drug	AndroGel 1.62%
Active ingredient	Testosterone
Dosage form	Topical transdermal gel
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Defendant	Hetero USA Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-00543
Case type	Hatch-Waxman patent infringement action
Plaintiffs	AbbVie Inc. and affiliated patent or product entities
Primary commercial issue	Timing of generic testosterone-gel entry

Hetero’s ANDA certification triggered AbbVie’s patent-infringement action under 35 U.S.C. § 271(e)(2). The statutory action is based on the filing of an ANDA with a Paragraph IV certification alleging that listed patents are invalid, unenforceable, or not infringed.

What patents protected AndroGel 1.62%?

The case concerned AbbVie’s intellectual-property position around testosterone-gel composition and use. The principal AndroGel patent family included patents directed to gel formulations, testosterone delivery, and treatment protocols.

Publicly associated AndroGel patents included the following:

Patent	General subject matter	Relevance to AndroGel
U.S. Patent No. 6,503,894	Testosterone gel composition and delivery	Earlier foundational formulation protection
U.S. Patent No. 7,320,968	Testosterone-gel treatment and administration	Method-of-use protection
U.S. Patent No. 8,435,944	Use of a 1.62% testosterone gel formulation	Core protection associated with AndroGel 1.62%
U.S. Patent No. 8,778,377	Related testosterone-gel formulation or use claims	Later-layer protection
U.S. Patent No. 8,821,913	Related testosterone product claims	Supplemental Orange Book protection

Patent relevance must be assessed by claim scope, not by the patent’s association with the brand. An ANDA applicant can avoid infringement by designing around particular concentration, excipient, dosing, application, or pharmacokinetic limitations.

The foundational AndroGel patents did not all expire at the same time. Earlier composition patents had materially shorter remaining terms, while later patents covering the 1.62% product and its use extended into the late 2020s. The applicable term for each patent depended on its filing history, patent-term adjustment, terminal disclaimers, and any regulatory patent-term extension.

When did AndroGel patents expire?

AndroGel’s exclusivity profile consisted of several overlapping periods rather than a single expiration date.

The principal timing points were:

• U.S. Patent No. 6,503,894 was associated with expiration around 2020, subject to applicable patent-term calculations.
• U.S. Patent No. 7,320,968 extended protection into the early 2020s.
• U.S. Patent No. 8,435,944 was associated with expiration in 2027.
• Related later-issued patents also carried potential expiration dates in the late 2020s.

FDA regulatory exclusivity and patent exclusivity operated separately. FDA’s five-year new chemical entity exclusivity did not apply in the same manner as patent protection for an approved testosterone product with an established active ingredient. The commercial barrier was therefore primarily the Orange Book patent estate and the litigation or settlement position of each ANDA applicant.

What was the litigation timeline in AbbVie v. Hetero?

The material procedural sequence was:

Date or period	Event
2014	AbbVie filed the Delaware action after Hetero submitted an ANDA with Paragraph IV certifications
2014-2015	Pleadings, patent-infringement allegations, and Hatch-Waxman case management proceeded
Case pendency	The parties resolved the dispute without a reported claim-construction, trial, or final invalidity decision
Termination	The action was dismissed pursuant to a settlement or stipulated resolution

The public case record does not establish a judicial finding that the asserted patents were valid, enforceable, and infringed. It also does not establish that Hetero’s ANDA product was adjudicated noninfringing. The absence of a merits opinion is commercially significant because the case did not create binding district-court precedent on the asserted AndroGel claims.

Did Hetero file a Paragraph IV challenge?

Yes. The action was a Paragraph IV Hatch-Waxman dispute. Hetero’s ANDA certification put AbbVie’s listed patents at issue before their scheduled expiration dates.

A Paragraph IV certification is not a regulatory rejection. It is an assertion that the applicant’s proposed product does not infringe the listed patent or that the patent is invalid or unenforceable. The filing of the infringement action generally creates a 30-month stay of FDA approval, subject to statutory exceptions and later court or regulatory events. The exact approval bar depends on the date and completeness of the patent-listing notice, the litigation record, and FDA’s treatment of the relevant ANDA.

What was the settlement outcome?

The case ended through settlement rather than a public judgment. The docket did not produce a reported opinion resolving patent validity, enforceability, infringement, or claim construction.

Publicly available litigation records generally do not disclose the full economic and launch terms of pharmaceutical settlements unless the parties file a reportable agreement with the Federal Trade Commission or Department of Justice, or otherwise place the terms on the record. The case docket therefore should not be treated as establishing a precise Hetero launch date unless that date is documented in the settlement agreement, a regulatory filing, or a later commercial event.

The likely commercial effect of the settlement was to define whether and when Hetero could market its testosterone gel before the expiration of the later AndroGel patents. Settlement-based entry can occur through a licensed launch date, a patent-expiration launch, or a contingent date tied to another generic entrant. The docket’s dismissal alone does not identify which structure applied.

What was the Orange Book status of AndroGel?

AndroGel’s Orange Book position was based on listed patents associated with the approved testosterone-gel product. Orange Book listings can include:

• Formulation patents covering the gel vehicle, concentration, or excipient system.
• Method-of-use patents covering treatment of testosterone deficiency or hypogonadism.
• Product-by-process or dosage-administration limitations, where properly listed.
• Later-issued patents added after the initial approval.

The Orange Book status must be evaluated by product strength and labeling. Patents listed against AndroGel 1.62% are not automatically applicable to AndroGel 1% or to every testosterone replacement product. The decisive question is whether the proposed ANDA label and formulation practice each asserted patent claim.

How strong was AbbVie’s AndroGel patent estate?

AbbVie’s estate had moderate-to-strong blocking value during the period of the Hetero litigation because it combined an earlier formulation platform with later patents directed specifically to the 1.62% product.

Its strengths were:

1. A branded product with an established FDA-approved label.
2. Multiple patent layers extending beyond the earliest composition patent.
3. Method-of-use claims that could create infringement exposure from the ANDA label.
4. A regulatory stay and the cost of district-court litigation.

Its constraints were equally material:

• Older patents faced prior-art and obviousness challenges.
• Method-of-use claims could be narrowed by label language and induced-infringement standards.
• A generic applicant could seek a noninfringing formulation or a Paragraph III certification against selected patents.
• A settlement eliminated the possibility of a public validity judgment that could have strengthened or weakened the estate for later challengers.

The litigation outcome therefore preserved commercial uncertainty rather than validating the entire patent portfolio.

Were biosimilar risks relevant to this case?

No. Hetero’s product was a small-molecule generic testosterone gel submitted under the ANDA pathway, not a biosimilar submitted under the Public Health Service Act.

The relevant risks were:

• Paragraph IV patent litigation.
• Formulation design-around risk.
• Label-based induced-infringement risk.
• FDA approval timing.
• Settlement restrictions on generic launch.

Biosimilar interchangeability, biologic reference-product exclusivity, and the Biologics Price Competition and Innovation Act were not the governing frameworks.

Which companies challenged AndroGel patents?

AndroGel faced broader generic competition beyond Hetero. Companies in the testosterone-gel market pursued ANDA strategies involving Paragraph III certifications, Paragraph IV certifications, patent litigation, or negotiated settlement.

The competitive field included major generic manufacturers and specialty pharmaceutical companies seeking approval for testosterone gels with comparable strengths and administration characteristics. Each applicant’s launch position depended on its own patent certifications and settlement terms. A settlement with Hetero did not establish the entry rights of other ANDA applicants.

What generic entry risks existed for AbbVie?

The principal generic-entry scenarios were:

Scenario	Commercial effect
Settlement-authorized early entry	Hetero launches before all listed patents expire under agreed conditions
Post-expiration entry	Hetero waits until the last enforceable blocking patent expires
Court victory for Hetero	FDA approval may proceed after removal of the litigation stay
Court victory for AbbVie	Hetero remains blocked until patent expiration or later settlement
Design-around approval	Hetero markets a product with a formulation or label that avoids asserted claims
Competing generic launch	Another applicant enters first, reducing the value of Hetero’s negotiated position

The greatest commercial risk was not limited to Hetero. Once one generic testosterone gel entered, price erosion could affect the entire topical testosterone category. Channel substitution, payer formulary changes, and authorized-generic strategies could accelerate revenue loss.

What revenue exposure did the litigation create?

AndroGel was a significant branded testosterone-replacement product, but product-level revenue attribution changed as AbbVie reorganized its portfolio and as testosterone products faced safety scrutiny, payer pressure, and generic substitution.

The litigation exposed AbbVie to three revenue risks:

• Loss of exclusivity for the 1.62% product.
• Rapid price erosion after generic entry.
• Spillover substitution from AndroGel into other testosterone formulations.

A precise case-specific revenue estimate cannot be derived from the docket. The relevant valuation measure is AndroGel 1.62% net sales multiplied by the expected generic erosion curve, adjusted for settlement timing, authorized-generic strategy, and remaining patent term.

Key Takeaways

• AbbVie Inc. v. Hetero USA Inc., No. 1:14-cv-00543, was a Delaware Hatch-Waxman action involving generic AndroGel 1.62% testosterone gel.
• Hetero’s Paragraph IV ANDA certification triggered the litigation.
• AbbVie relied on a layered estate covering testosterone-gel formulations, the 1.62% product, and methods of use.
• The case ended by settlement or stipulated dismissal without a reported merits decision.
• The public record does not establish a judicial ruling that the asserted patents were valid, enforceable, and infringed.
• The dispute involved generic, not biosimilar, competition.
• Commercial risk depended on the confidential settlement terms, the remaining AndroGel patent term, and the timing of other generic entrants.

FAQs About AbbVie v. Hetero USA

What product did Hetero seek to genericize?

Hetero sought approval for a generic version of AndroGel 1.62%, a topical testosterone gel used for testosterone replacement.

Was AbbVie v. Hetero a patent trial?

No reported trial or final merits opinion resolved the case. The action terminated through a negotiated or stipulated resolution.

Did Hetero receive an authorized launch date?

The public docket does not provide a judicially established launch date. A binding launch date would depend on the settlement and related regulatory records.

Did the case invalidate any AndroGel patent?

No. The case did not produce a reported decision invalidating the asserted AndroGel patents.

Could Hetero’s product have avoided infringement?

Yes. An ANDA applicant can pursue noninfringement through a different formulation, concentration, excipient profile, dosing instruction, or label, subject to FDA approval and the scope of the asserted claims.

References

1. AbbVie Inc. v. Hetero USA Inc., No. 1:14-cv-00543, U.S. District Court for the District of Delaware, docket records.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 6,503,894, 7,320,968, and 8,435,944.
4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
5. Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).